Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34368408

about

Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy Targeting the androgen receptor in prostate and breast cancer: several new agents in development Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Targeting the adaptive molecular landscape of castration-resistant prostate cancer Molecular Imaging of Prostate Cancer Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Molecular pathways and targets in prostate cancer Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Safety of antiandrogen therapy for treating prostate cancer.Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.Androgen receptor: structure, role in prostate cancer and drug discovery.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Molecular imaging of urogenital diseases.Update in systemic therapy of urologic malignancies.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer.PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects Evolution of androgen receptor targeted therapy for advanced prostate cancer.Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer Advances in systemic therapies for metastatic castration-resistant prostate cancer.Nonmetastatic castration-resistant prostate cancer.Metastatic castration-resistant prostate cancer: time for innovation.Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Synergistic action of image-guided radiotherapy and androgen deprivation therapy.Sequences and combinations of multifaceted therapy in advanced prostate cancer.Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

P2860

Q21129293-ABDBC21A-0E2A-46D1-B6AB-BAB3CED7A761 Q26750620-958ADA92-6D7D-45E8-93B1-77C2E80F641E Q26796568-F96764FD-6B9E-4C70-9897-21007C16D6AA Q26825053-B1303F21-9EB6-4C3B-818D-93F812238944 Q27009424-3804A1E5-846F-4EE1-8740-428CABD1866D Q27011642-4BB3473A-0B8B-49CF-AFC5-D3E46E0B94BD Q27022821-48223ED5-72D6-4C4E-B930-825B79338947 Q33620520-47B107E9-EFC1-4285-A718-E35281BE5483 Q33656820-E9CF7529-CE11-460D-BE8C-C8728AF71828 Q33775717-DB2F512E-2979-4A0B-B48C-66DAAA59F994 Q34365632-2516069F-50C1-4828-9596-AD50F7C8DF64 Q34375823-1A2AFC79-11AA-4415-BFDC-20850FB85B1C Q34441134-77439FF9-E508-4F54-BFC8-08F32577C67F Q34495028-C9C06955-46C4-4F42-A6D1-5630E7497EFE Q35213324-619A87AB-A505-476A-B1CF-646EE2C6CA0D Q35553876-AF3CBB56-1EE8-4CA0-BEFC-6CCD4A29B790 Q35931391-897C4438-BB12-40D4-8F7B-66F040904A9A Q36063723-413751BC-8AAC-4E25-8310-DEE494C431E6 Q36298863-66D6507B-DD7B-42C8-BF3B-4E0B8225E6D2 Q36849142-0894D6D0-7A87-47A9-9D7F-1E6E4F92471A Q36905832-0339F250-B4E7-4067-89CD-04FB9D39A291 Q36970812-E8568724-6239-4966-9993-DB694D4FFB60 Q37550399-525A81E8-89ED-4BDB-8100-AA8D1A25D781 Q38176143-D0A7C492-9292-422F-A7D0-F7110CE3A74F Q38184622-39A08AEE-B45D-43F3-BFAF-FA6C66FFC342 Q38195723-C1AECB62-D7EB-4F9B-83F1-61C8453D45F8 Q38206682-31BA6B09-7B12-40BE-B0D6-68C0823BB8F3 Q38212470-F8944341-6B9F-462F-9421-D7B065BF2ED5 Q38212716-2C995549-DF68-44EA-9981-D3E34EC3AE62 Q38220073-F7436E6F-18CC-44FC-9A48-C4A809F5FE38 Q38259197-36DA9649-89DB-4E46-A068-EBAC98028547 Q38267175-0818565B-6DE8-4A35-8DFB-A4A2A364C534 Q38276818-DB80CEA1-74D6-4BBA-B11D-D56B7FE56DD6 Q38282461-1DDF6B83-6972-47E3-B744-922DC0E94CA5 Q38306052-FA4B6B0E-D207-407D-BAB9-738BC0B71DAA Q38312041-D22E11A0-0CD8-41A9-B0DC-D6908268D8E8 Q38375252-BD64C6F8-4A81-482D-B8A9-D2C0AAE60846 Q38387844-96D61A8F-C743-4E0C-9084-3349E1A25678 Q38391800-B8BFE387-2320-48DC-B832-FBC25DCE574B Q38392787-318BC47F-8A70-432E-8CF0-3E3F6A0773BF

P2860

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34368408

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@ast

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@en

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@nl

type

label

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@ast

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@en

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@nl

prefLabel

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@ast

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@en

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@nl

P1433

Q34368408-778A2A8F-A89F-488C-974D-0B16912DD62B

P1476

Q34368408-46ABC71C-8FA6-4F53-BA8F-7D04F229E459

P2093

Q34368408-321A4585-DB8B-45C6-80EB-B687776C9C61

Q34368408-51F338E5-85D8-40F4-BCC7-E058DEED823A

Q34368408-6123FA18-54BA-4900-B8AD-23771653A302

Q34368408-7B54A509-7C3A-4DDA-9DF2-68D99C9CDBA3

Q34368408-7DD11E35-8E6D-4E74-9B90-D8C1A8FB07B5

Q34368408-860AE0E4-9F1E-4677-AFBB-F829F599BE95

Q34368408-8B0553EC-1912-43FD-8A0E-24A62F84CE35

Q34368408-9F8C56FB-CD82-4D33-874E-1DD2895771A5

Q34368408-B4862D9B-B638-4654-93A4-D3249D30F9EB

Q34368408-C67281D7-966C-42BF-9433-41ED335C61FF

P2860

Q34368408-1F198433-E7F5-4237-840E-BD848D7752B2

Q34368408-387CFFF9-EF01-487D-A377-E3EA099334C7

Q34368408-6A537FC7-91CE-484C-A952-3761B6955A5F

Q34368408-6C71B949-CAC5-4D21-8E32-9BE076B23EB8

Q34368408-76A4EF3E-1261-423E-9A20-22660D9658DE

Q34368408-7A69A20F-0B22-4EDF-975A-81F1FAC46B68

Q34368408-98239CD9-D170-475D-8AB0-913477A56A9E

Q34368408-A12083DF-5E0D-4036-B0A3-99B581C4C4B4

Q34368408-A8E54F5B-E09F-4B41-AE5F-F383A12AD844

Q34368408-C6B65A26-A1F4-4619-928F-7DAD8312C8B8

P304

Q34368408-50088745-0D83-44F2-AD14-776B95FDE18D

P31

Q34368408-9CED45B8-0030-49E8-BE56-E22D9FAFC12C

P356

Q34368408-B45EEFDC-5D0A-462D-929A-5804ACD4A58E

P407

Q34368408-4C74F88A-DF22-49F8-AC08-AC971BA13F98

P433

Q34368408-BE47A352-2D7F-4748-A47E-66DE46CF016F

P478

Q34368408-CA0A6BF5-03DB-42AA-B0E3-3969C06AD689

P50

Q34368408-6D18E9BB-55C4-43C7-BFBE-BC8167FE6169

Q34368408-920E9965-218C-41DA-9C3C-7F2F65503D22

P577

Q34368408-F45D37BC-5C66-49A8-83DD-C25163E0503B

P698

Q34368408-280EDC83-EDBB-4DFC-A878-503A19DE21DB

P932

Q34368408-5A1BD1CB-7220-42B9-98C8-44037B308A80

P356

JCO.2013.50.1684

P1433

Journal of Clinical Oncology

P1476

Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.

@en

P2093

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

Daniel C Danila

http://www.w3.org/2001/XMLSchema#string

Edna Chow Maneval

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Isan Chen

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Hager

http://www.w3.org/2001/XMLSchema#string

Josef J Fox

http://www.w3.org/2001/XMLSchema#string

Martin Fleisher

http://www.w3.org/2001/XMLSchema#string

Michael J Morris

http://www.w3.org/2001/XMLSchema#string

Mithat Gönen

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer

Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular determinants of resistance to antiandrogen therapy

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

P304

3525-3530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.50.1684

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Dana E Rathkopf

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24002508

http://www.w3.org/2001/XMLSchema#string

P932

3782148

http://www.w3.org/2001/XMLSchema#string